8-K
filed June 28, 2023, 7:59 PM ET
ticker TXMD
CIK 0000025743
other material
confidence high
sentiment neutral
materiality 0.15
TherapeuticsMD stockholders approve charter amendment and private placement at 2023 annual meeting
TherapeuticsMD, Inc.
- Elected all four director nominees (Thompson, Collins, Naughton, Roberts) with over 4 million 'for' votes each.
- Approved charter amendment to increase authorized common shares from 12 million to 32 million with 5,431,781 votes for.
- Approved private placement of up to 5 million shares to Rubric Capital Management with 4,178,998 votes for.
- Non-binding advisory vote on named executive officer compensation passed with 4,007,930 votes for.
- Ratified Grant Thornton LLP as independent auditor for fiscal 2023 with 5,875,689 votes for.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
TherapeuticsMD, Inc. shareholders approved Ratification of appointment of Grant Thornton LLP as independent auditor for fiscal year 2023 at the 2023-06-26 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-26
Exact text from the filing
The Company’s stockholders ratified the appointment of Grant Thornton, LLP, an independent registered public accounting firm, as the independent auditor of the Company for the fiscal year ending December 31, 2023, by the votes set forth in the table below: For Against Abstain Broker Non- Votes 5,875,689 162,089 13,371 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
TherapeuticsMD, Inc. shareholders approved Non-binding advisory vote on named executive officer compensation for fiscal year 2022 at the 2023-06-26 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-26
Exact text from the filing
The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2022, by the votes set forth in the table below: For Against Abstain Broker Non- Votes 4,007,930 317,286 98,143 1,627,790
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
TherapeuticsMD, Inc. shareholders approved Approval of amendment to Amended and Restated Articles of Incorporation to increase authorized shares of Common Stock from 12,000,000 to 32,000,000 at the 2023-06-26 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-06-26
Exact text from the filing
The Company’s stockholders approved the Charter Amendment, by the votes set forth in the table below: For Against Abstain Broker Non- Votes 5,431,781 595,133 24,235 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
TherapeuticsMD, Inc. shareholders approved Approval of issuance of up to 5,000,000 shares of Common Stock in private placements to Rubric Capital Management LP under Nasdaq Rules 5635(b) and 5635(d) at the 2023-06-26 meeting.
- Outcome
- passed
- Meeting
- 2023-06-26
Exact text from the filing
The Company’s stockholders approved the Private Placement Proposal, by the votes set forth in the table below: For Against Abstain Broker Non- Votes 4,178,998 238,644 5,717 1,627,790
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
TherapeuticsMD, Inc. shareholders approved Election of four directors at the 2023-06-26 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-26
Exact text from the filing
All of the four nominees for the Company’s Board of Directors were elected to serve until the Company’s next annual meeting of stockholders or until their successors are duly elected and qualified, by the votes set forth in the table below: Nominee For Withheld Broker Non-Votes Tommy G. Thompson 4,124,794 298,565 1,627,790 Cooper C. Collins 4,149,214 274,145 1,627,790 Gail K. Naughton, Ph.D. 4,153,469 269,890 1,627,790 Justin Roberts 4,085,664 337,695 1,627,790
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.